Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Kumari S, Samant M, Khare P, Misra P, Dutta S, Kolli BK, Sharma S, Chang KP, Dube A.

Eur J Immunol. 2009 Jan;39(1):178-91. doi: 10.1002/eji.200838389.

3.
4.

Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.

Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A.

J Immunol. 2011 Dec 15;187(12):6417-27. doi: 10.4049/jimmunol.1102081. Epub 2011 Nov 11.

5.

Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis.

Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL.

J Immunol. 2009 Aug 1;183(3):1813-20. doi: 10.4049/jimmunol.0900276. Epub 2009 Jul 10.

6.

Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.

Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A.

Vaccine. 2008 Oct 23;26(45):5700-11. doi: 10.1016/j.vaccine.2008.08.021. Epub 2008 Aug 30.

PMID:
18762224
7.

Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Shahbazi M, Zahedifard F, Taheri T, Taslimi Y, Jamshidi S, Shirian S, Mahdavi N, Hassankhani M, Daneshbod Y, Zarkesh-Esfahani SH, Papadopoulou B, Rafati S.

PLoS One. 2015 Jul 21;10(7):e0132794. doi: 10.1371/journal.pone.0132794. eCollection 2015.

8.

Delta-aminolevulinate-induced host-parasite porphyric disparity for selective photolysis of transgenic Leishmania in the phagolysosomes of mononuclear phagocytes: a potential novel platform for vaccine delivery.

Dutta S, Chang C, Kolli BK, Sassa S, Yousef M, Showe M, Showe L, Chang KP.

Eukaryot Cell. 2012 Apr;11(4):430-41. doi: 10.1128/EC.05202-11. Epub 2012 Feb 3.

9.
10.
11.

Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.

Fiuza JA, Gannavaram S, Santiago Hda C, Selvapandiyan A, Souza DM, Passos LS, de Mendonça LZ, Lemos-Giunchetti Dda S, Ricci ND, Bartholomeu DC, Giunchetti RC, Bueno LL, Correa-Oliveira R, Nakhasi HL, Fujiwara RT.

Vaccine. 2015 Jan 3;33(2):280-8. doi: 10.1016/j.vaccine.2014.11.039. Epub 2014 Dec 1.

PMID:
25475955
12.

Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.

Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A.

Parasitol Res. 2014 Mar;113(3):851-62. doi: 10.1007/s00436-013-3716-5. Epub 2013 Dec 27.

PMID:
24370734
13.

Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.

Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.

Scand J Immunol. 2008 Nov;68(5):492-501. doi: 10.1111/j.1365-3083.2008.02171.x. Epub 2008 Sep 18.

14.

Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi.

DE Oliveira Gomes DC, DA Silva Costa Souza BL, DE Matos Guedes HL, Lopes UG, Rossi-Bergmann B.

Parasitology. 2011 Dec;138(14):1892-7. doi: 10.1017/S0031182011001417. Epub 2011 Aug 26.

PMID:
21867591
15.

Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation.

Carrión J, Folgueira C, Soto M, Fresno M, Requena JM.

Parasit Vectors. 2011 Jul 27;4:150. doi: 10.1186/1756-3305-4-150.

16.

Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.

Nagill R, Kaur S.

Vaccine. 2010 May 21;28(23):4002-12. doi: 10.1016/j.vaccine.2010.01.015. Epub 2010 Jan 19.

PMID:
20093205
17.

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.

Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.

Vaccine. 2007 May 22;25(21):4223-34. Epub 2007 Mar 15.

PMID:
17395339
18.

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

Saljoughian N, Zahedifard F, Doroud D, Doustdari F, Vasei M, Papadopoulou B, Rafati S.

Parasite Immunol. 2013 Dec;35(12):397-408. doi: 10.1111/pim.12042.

19.

Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.

Thakur A, Kaur H, Kaur S.

Parasitol Int. 2015 Feb;64(1):70-8. doi: 10.1016/j.parint.2014.10.003. Epub 2014 Oct 12.

PMID:
25316605
20.

Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.

Baharia RK, Tandon R, Sharma T, Suthar MK, Das S, Siddiqi MI, Saxena JK, Sundar S, Dube A.

PLoS Negl Trop Dis. 2015 Mar 6;9(3):e0003557. doi: 10.1371/journal.pntd.0003557. eCollection 2015 Mar. Erratum in: PLoS Negl Trop Dis. 2015 Apr;9(4):e0003742. Sunder, Shyam [corrected to Sundar, Shaym].

Supplemental Content

Support Center